English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 6 February 2026, 11:14 JST
Share:
    

Source: Fujitsu Ltd
Fujitsu Japan and JMDC announce collaboration to build sustainable healthcare system in Japan through enhanced medical data utilization

Kawasaki and Tokyo, Japan, Feb 6, 2026 - (JCN Newswire) - Fujitsu Japan Limited and JMDC Inc. today announced the commencement of a collaboration aimed at advancing medical care and contributing to the establishment of a sustainable healthcare system in Japan.

This collaboration, which began on January 5, leverages JMDC's expertise in utilizing anonymized medical data and Fujitsu Japan's customer base. Fujitsu Japan holds the top share in the Japanese electronic health record (EHR) market for medical institutions. This synergy will accelerate the utilization of medical data by medical institutions and organizations that are part of the healthcare system, while also supporting data-driven management decision-making.

This collaboration will see the two companies combine Fujitsu Japan's knowledge in the medical field and advanced technologies including AI, with JMDC's prediction models based on insurance user data and its expertise cultivated through Pep Up, one of Japan's largest personal health record services used by 7.7 million people. This will expand the scope of data utilization from DPC data [1] to comprehensive EHR data. This initiative will further promote the utilization of medical data, contributing to improved management for medical institutions and advanced research for pharmaceutical companies, government agencies, and academia.

Going forward, Fujitsu Japan will contribute to the realization of digital hospitals that promote DX in medical institutions, while JMDC will advance initiatives that contribute to "building a sustainable healthcare system through addressing social issues with the power of data and ICT" and "accelerating the societal integration of data."

Overview of the collaboration

Fujitsu Japan will provide Dashboard 360, a solution that enables visualization and analysis of management and clinical data, free of charge [2] to medical institutions that agree to provide anonymized DPC data [3]. Dashboard 360 is offered as part of Fujitsu Limited's Uvance business model, which addresses societal challenges, specifically within the Smart Hospital offering that maximizes hospital operational efficiency and effectiveness. It is a component of the Healthcare Management Platform, a suite of services designed to optimize patient flow [4] in acute care hospitals and support the resolution of management challenges.

Dashboard 360 seamlessly integrates with EHRs, allowing for factor analysis of issues such as declining bed occupancy rates and waiting times for hospitalization or surgery, based on information including inpatient care and outpatient conditions leading to hospitalization. It also features a benchmarking function, utilizing data provided by JMDC and DPC data from medical institutions, to support timely decision-making in hospital management.

JMDC will collaborate with Fujitsu Japan to anonymize DPC data in a secure environment and provide it to pharmaceutical companies, government agencies, and universities for research purposes. Additionally, by combining this with JMDC's accumulated insurance user data, covering approximately 20 million individuals, the collaboration will visualize the entire patient journey from pre-onset abnormal test results to inpatient treatment and post-discharge prognosis. This will enable early detection of diseases through screening of potential patients, prevention of severe cases by identifying risk factors, and precise evaluation of long-term treatment effects and drug safety in real-world settings, thereby contributing to the improvement of medical quality and efficiency.

Figure: Collaboration overview

Background

In Japan, the aging population and increasing medical expenses are pressing concerns. Challenges such as a shortage of healthcare professionals and financial difficulties for medical institutions persist. By leveraging medical data, it is expected that these challenges can be addressed through improved diagnostic accuracy, enhanced operational efficiency, development of new treatment methods, and strengthened regional healthcare collaboration.

[1] DPC data:
Data used to calculate medical costs based on the patient's diagnosis and treatment content during hospitalization. It includes patient information, diagnoses, surgical procedures, medications used, and is expected to be utilized for analyzing medical quality and hospital management, as well as for formulating healthcare policies.
[2] Agreement to provide anonymized DPC data:
Fujitsu Japan is entrusted by medical institutions with the creation of anonymized information such as DPC data, and the medical institutions grant Fujitsu Japan permission for secondary use of the created anonymized information.
[3] Free of charge:
No initial setup or usage fees. A separate license fee for the BI tool included in the service is required.
[4] Patient flow:
The management of the entire patient process from hospital visit to discharge.

About Fujitsu

Fujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu

About JMDC

Established in 2002 as a pioneer in the medical big data industry, JMDC possesses proprietary anonymization processing technology and data analysis/aggregation technology. Based on the analysis of over 1.573 billion medical claims data and over 76 million health checkup data (as of March 2025), JMDC provide information services, including support for health promotion programs for payers, drug safety evaluation, and healthcare economics analysis. JMDC is committed to realizing a healthy society through medical data and analytical capabilities, providing a single index for health (Health Age) and web services for health promotion (Pep Up), among others. Find out more: https://www.jmdc.co.jp/en/

Press Contacts

Fujitsu Limited
Public and Investor Relations Division
Inquiries

JMDC Inc.
JMDC Inc. IR Office
Email: jmdc-pr@jmdc.co.jp



Topic: Press release summary
Source: Fujitsu Ltd

Sectors: Healthcare & Pharm, Digitalization, Artificial Intel [AI]
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 
Fujitsu Ltd Links

http://www.fujitsu.com

https://plus.google.com/+Fujitsu

https://www.facebook.com/FujitsuJapan

https://twitter.com/Fujitsu_Global

https://www.youtube.com/user/FujitsuOfficial

https://www.linkedin.com/company/fujitsu/

Fujitsu Ltd Related News
Friday, 6 February 2026, 10:44 JST
Genesys and Fujitsu Transform AEON Financial Service's Contact Center Operations with Genesys Cloud Delivers Customers an Improved Self-Service Experience Resulting in Higher Completion and Reduced Wait Times
2026年2月3日 14時30分 JST
富士通、パブリックコメント業務に大規模言語モデル「Takane」を活用し、中央省庁で業務効率化の実証実験を実施
Tuesday, 3 February 2026, 11:14 JST
Fujitsu's Takane LLM successfully piloted in central government agency to streamline public comment operations
Monday, 2 February 2026, 16:29 JST
Lockheed Martin and Fujitsu to accelerate dual-use technology development
Monday, 2 February 2026, 14:30 JST
Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575